

Figure S1. Subgroup analyses for progression-free survival from second-line treatment. IBP, immunotherapy beyond progression; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval.




Figure S2. Subgroup analyses for overall survival. IBP, immunotherapy beyond progression; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; CI, confidence interval.




Figure S3. Kaplan-Meier curves of (A) PFS2 and (B) OS for the patients who were treated with three agents (chemo + IO + anti-angio) and for the patients who were treated with two agents (chemo + IO). Chemo, chemotherapy; IO, immunotherapy; anti-angio, anti-angiogenic therapy; PFS2, progression-free survival from second-line treatment; OS, overall survival.

